Procter & Gamble has rolled out new Head & Shoulders formulations featuring the HydraZinc Complex and expanded its Oral-B iO line, emphasizing clinically tested scalp and oral care technologies now available across multiple product collections in the U.S. market. The launches reflect the company's push to lean on science-led product innovation to reinforce its brands and support a broader shift from pricing-driven growth toward offering more tangible consumer value. The expansion of the premium Oral-B iO range is the most relevant piece for the investment case, as it ties directly into P&G's effort to improve its mix with higher value, technology-rich products. Procter & Gamble's narrative projects $94.5 billion in revenue and $18.2 billion in earnings by 2029, requiring 2.8% yearly revenue growth and about a $2.4 billion earnings increase from $15.8 billion today. The biggest current risk remains input cost and FX headwinds that could pressure margins and near term EPS.
Procter & Gamble CompanyP&G launched new Head & Shoulders HydraZinc formulations and expanded its premium Oral-B iO line, science-led product innovation that improves product mix.
